MGC018 clinical trials

A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

This study is looking at a new medicine called MGC018 (also known as vobramitamab duocarmazine) for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. Researchers want to see how well it works and if it's safe at two different dose levels.